Starpharma (ASX:SPL) see revenue rise 142%

27Aug

Starpharma (ASX:SPL) see revenue rise 142%

 

Starpharma (ASX:SPL) report their revenue is up 142 per cent to $6.56 million.

The increase in revenue reflects the AstraZeneca $4.3 million development milestone.

The company still reported loss after tax is $14.7 million from the expense of all research and development expenditure and patenting costs associated with VivaGel® and DEP® programs.

Shares in Starpharma (ASX:SPL) are trading 5.6 per cent higher at $1.41.
 
Copyright 2020 – Finance News Network


Source: Finance News Network

Share this post

Related Posts

19Apr

Stocks of the Hour: DY6 Metals, Impact Minerals, Estrella Resources

19 Apr 2024 - A snapshot of the stocks on the move, featuring DY6 Metals, Impact Minerals and Estrella Resources.

Read More
17Jun

Stocks of the Hour: Coles, Whitehaven Coal, Sonic Healthcare, Seven West Media

17 Jun 2021 - Our snapshot of company news making headlines featuring Coles (ASX:COL), Whitehaven Coal (ASX:WHC), Sonic Healthcare (ASX:SHL) and Seven West Media (ASX:SWM).

Read More
03Mar

Santos (ASX:STO) see major contracts awarded for the Barossa Project

03 Mar 2020 - Santos (ASX:STO) today announced the award of contracts for the supply and installation of subsea infrastructure for the Barossa project.

Read More
12Dec

Stocks of the Hour: Midas Minerals, Riversgold, Lithium Australia

12 Dec 2023 - A snapshot of the stocks on the move, featuring Midas Minerals (ASX:MM1), Riversgold (ASX:RGL) and Lithium Australia (ASX:LIT).

Read More
29Jun

Official Ampol (ASX:ALD) MD & CEO appointment

29 Jun 2020 - Ampol (ASX:ALD) has officially appointed their current Interim Chief Executive Officer Matthew Halliday to Managing Director and Chief Executive Officer.

Read More
20Jan

Gentrack Group (ASX:GTK) downgrades FY20 outlook

20 Jan 2020 - Gentrack Group (ASX:GTK) has downgraded its outlook for the 2020 financial year.

Read More
03Feb

Invion (ASX:IVX) secures services agreement with Pavay Biotech

03 Feb 2020 - A subsidiary of Invion (ASX:IVX), EpiTech Dermal Science, has signed an R&D services agreement with a leading China-based pharmaceutical group in the skin repair and treatment market.

Read More
26Jul

Stocks of the Hour: Empire Energy, E79 Gold Mines, Cyprium Metals

26 Jul 2024 - A snapshot of the stocks on the move, featuring Empire Energy (ASX:EEG), E79 Gold Mines (ASX:E79) and Cyprium Metals (ASX:CYM).

Read More
13Feb

Stocks of the Hour: Dateline Resources, Blue Energy, Ansarada Group

13 Feb 2024 - A snapshot of the stocks on the move, featuring Dateline Resources (ASX:DTR), Blue Energy (ASX:BLU) and Ansarada Group (ASX:AND).

Read More
06Mar

Cashwerkz (ASX:CWZ) establish pilot program with Mozo

06 Mar 2020 - Cashwerkz (ASX:CWZ) announced today it is establishing a pilot program with Mozo to deliver Cashwerkz innovative term deposits to consumers via the Mozo platform.

Read More